The European Journal of Health Economics

, Volume 12, Issue 1, pp 49–59

Generic substitution: micro evidence from register data in Norway

  • Dag Morten Dalen
  • Kari Furu
  • Marilena Locatelli
  • Steinar Strøm
Original Paper

DOI: 10.1007/s10198-010-0226-6

Cite this article as:
Dalen, D.M., Furu, K., Locatelli, M. et al. Eur J Health Econ (2011) 12: 49. doi:10.1007/s10198-010-0226-6

Abstract

The importance of prices, doctor and patient characteristics, and market institutions for the likelihood of choosing generic drugs instead of the more expensive original brand-name version are examined. Using an extensive dataset extracted from The Norwegian Prescription Database containing all prescriptions dispensed to individuals in February 2004 and 2006 on 23 different drugs (chemical substances) in Norway, we find strong evidence for the importance of both doctor and patient characteristics for the choice probabilities. The price difference between brand and generic versions and insurance coverage both affect generic substitution. Moreover, controlling for the retail chain affiliation of the dispensing pharmacy, we find that pharmacies play an important role in promoting generic substitution. In markets with more recent entry of generic drugs, brand-name loyalty proves to be much stronger, giving less explanatory power to our demand model.

Keywords

Pharmaceutical industry Generic substitution Microdata Random utility model 

JEL Classifications

C 35 I 11 L 13 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Dag Morten Dalen
    • 1
  • Kari Furu
    • 2
  • Marilena Locatelli
    • 3
  • Steinar Strøm
    • 3
  1. 1.BI Norwegian School of ManagementOsloNorway
  2. 2.The Norwegian Institute of Public HealthOsloNorway
  3. 3.University of Turin and the Frisch CentreOsloNorway